1. Home
  2. SLN vs SY Comparison

SLN vs SY Comparison

Compare SLN & SY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • SY
  • Stock Information
  • Founded
  • SLN 1994
  • SY 2013
  • Country
  • SLN United Kingdom
  • SY China
  • Employees
  • SLN N/A
  • SY N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • SY EDP Services
  • Sector
  • SLN Health Care
  • SY Technology
  • Exchange
  • SLN Nasdaq
  • SY Nasdaq
  • Market Cap
  • SLN 345.3M
  • SY 289.0M
  • IPO Year
  • SLN N/A
  • SY 2019
  • Fundamental
  • Price
  • SLN $6.24
  • SY $4.21
  • Analyst Decision
  • SLN Buy
  • SY Strong Buy
  • Analyst Count
  • SLN 6
  • SY 1
  • Target Price
  • SLN $39.67
  • SY $5.50
  • AVG Volume (30 Days)
  • SLN 213.8K
  • SY 1.1M
  • Earning Date
  • SLN 11-07-2025
  • SY 11-17-2025
  • Dividend Yield
  • SLN N/A
  • SY 0.63%
  • EPS Growth
  • SLN N/A
  • SY N/A
  • EPS
  • SLN N/A
  • SY N/A
  • Revenue
  • SLN $27,169,000.00
  • SY $197,807,588.00
  • Revenue This Year
  • SLN N/A
  • SY $8.61
  • Revenue Next Year
  • SLN N/A
  • SY $54.55
  • P/E Ratio
  • SLN N/A
  • SY N/A
  • Revenue Growth
  • SLN 22.28
  • SY N/A
  • 52 Week Low
  • SLN $1.97
  • SY $0.66
  • 52 Week High
  • SLN $18.24
  • SY $6.28
  • Technical
  • Relative Strength Index (RSI)
  • SLN 46.82
  • SY 67.79
  • Support Level
  • SLN $7.06
  • SY $2.81
  • Resistance Level
  • SLN $7.39
  • SY $3.22
  • Average True Range (ATR)
  • SLN 0.58
  • SY 0.25
  • MACD
  • SLN -0.12
  • SY 0.12
  • Stochastic Oscillator
  • SLN 21.87
  • SY 89.78

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About SY So-Young International Inc. American Depository Shares

So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.

Share on Social Networks: